Literature DB >> 17547836

Antihypertensive agents, insulin sensitivity, and new-onset diabetes.

Pantelis A Sarafidis1, Samy I McFarlane, George L Bakris.   

Abstract

The effects of the antihypertensive drugs on carbohydrate metabolism and the development of diabetes have been a major research field for more than two decades. Many clinical studies have investigated the effects of the antihypertensive classes on insulin sensitivity and glycemic control, whereas several observational studies and large outcome trials have examined associations of antihypertensive agents with diabetes incidence. In general, thiazide diuretics and conventional beta blockers decrease insulin sensitivity and increase new-onset diabetes, whereas angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin II receptor blockers have neutral or beneficial effects on these parameters. However, several issues in this field, such as the specific properties of newer agents and the relationship of adverse metabolic outcomes and cardiovascular risk, remain to be fully elucidated. This article presents and evaluates the current knowledge in this important area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547836     DOI: 10.1007/s11892-007-0031-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  71 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  S I McFarlane; M Banerji; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

Authors:  Ralf A Benndorf; Tanja Rudolph; Daniel Appel; Edzard Schwedhelm; Renke Maas; Friedrich Schulze; Elisabeth Silberhorn; Rainer H Böger
Journal:  Metabolism       Date:  2006-09       Impact factor: 8.694

Review 4.  New treatment strategies for patients with hypertension and insulin resistance.

Authors:  Theodore W Kurtz
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

5.  A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients.

Authors:  D Lender; C Arauz-Pacheco; L Breen; P Mora-Mora; L C Ramirez; P Raskin
Journal:  Am J Hypertens       Date:  1999-03       Impact factor: 2.689

6.  Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

Authors:  David V Erbe; Katherine Gartrell; Yan-Ling Zhang; Vipin Suri; Steven J Kirincich; Sarah Will; Mylene Perreault; Suyue Wang; James F Tobin
Journal:  Vascul Pharmacol       Date:  2006-05-16       Impact factor: 5.773

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

8.  Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.

Authors:  A Haenni; H Lithell
Journal:  J Hypertens Suppl       Date:  1999-08

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension.

Authors:  R Harper; C N Ennis; B Sheridan; A B Atkinson; G D Johnston; P M Bell
Journal:  BMJ       Date:  1994-07-23
View more
  8 in total

1.  Does it matter how we lower blood pressure in obese hypertensive patients?

Authors:  Arya M Sharma
Journal:  Curr Hypertens Rep       Date:  2008-02       Impact factor: 5.369

2.  Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Authors:  Lu Chen; Jessica Chubak; Denise M Boudreau; William E Barlow; Noel S Weiss; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-08-14       Impact factor: 4.254

3.  Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.

Authors:  Elizabeth O Ofili; Dion H Zappe; Das Purkayastha; Rita Samuel; James R Sowers
Journal:  Am J Ther       Date:  2013-01       Impact factor: 2.688

Review 4.  Lipid effects of antihypertensive medications.

Authors:  Roderick Deano; Matthew Sorrentino
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

5.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

6.  Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yuxiu Xie; Men Wang; Peng Xu; Yujiao Deng; Yi Zheng; Si Yang; Ying Wu; Zhen Zhai; Dai Zhang; Na Li; Nan Wang; Jing Cheng; Zhijun Dai
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

7.  ASH position paper: treatment of hypertension in patients with diabetes-an update.

Authors:  George L Bakris; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-09       Impact factor: 3.738

8.  Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies.

Authors:  Haibo Ni; Qin Rui; Xiaojue Zhu; Zhenquan Yu; Rong Gao; Huixiang Liu
Journal:  Oncotarget       Date:  2017-07-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.